Phaseline

Companies › Avirmax Biopharma

Avirmax Biopharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Ophthalmology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ABI-110
AAV2-delivered VEGF Trap
VEGFAPhase 1Neovascular (Wet) AMDJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06550011ABI-110Phase 1Neovascular (Wet) AMDOphthalmologyJan 2027

Targets

VEGFA (1)

Companies with the same targets

Roche Jiangsu Simcere Pharmaceutical Chengdu Origen Biotechnology Biotheus AstraZeneca Prestige Biopharma Eli Lilly 4D Molecular Therapeutics PPD Development, LP Shanghai Henlius Biotech

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.